Connor, Clark & Lunn Investment Management (CC&L)
ELVN icon

Connor, Clark & Lunn Investment Management (CC&L)’s Enliven Therapeutics ELVN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16M Sell
160,879
-30,414
-16% -$1.29M 0.02% 589
2026
Q1 		$7.5M Sell
191,293
-3,442
-2% -$95.4K 0.02% 559
2025
Q4 		$3M Buy
194,735
+159,956
+460% +$3.19M 0.01% 813
2025
Q3 		$712K Buy
+34,779
New +$701K ﹤0.01% 1165

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ELVN Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Enliven Therapeutics (ELVN) stake by 16% in Q2 2026, selling an estimated $1.29M and leaving 160,879 shares worth $8.16M. The position accounts for 0.02% of the portfolio, ranked #589.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ELVN in Q3 2025 and has held it in 4 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 160,879 shares of Enliven Therapeutics worth $8.16M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 30,414 Enliven Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Enliven Therapeutics made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #589 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Enliven Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.